Multimorbidity

Multimorbidity is not merely a count of diagnoses. The important clinical problem is interaction: one condition may change the presentation or treatment of another, while appointments, monitoring and self-management compete for limited time, money and energy. A patient with diabetes, heart failure, osteoarthritis and depression can receive individually correct recommendations that are collectively exhausting or unsafe. The aim is coherent care, not perfect compliance with every isolated disease target.

NICE NG56 applies to adults with two or more long-term health conditions, which may be physical, mental or both; its scope gives examples rather than requiring a physical condition. It recommends identifying people who may benefit from a multimorbidity approach, particularly when they find treatment burdensome, have frailty or falls, take multiple medicines, use unplanned care or have difficulty managing daily activities. Diagnosis count alone neither mandates nor excludes an individualised review.

Begin with goals and lived impact. Ask what the person most wants to preserve or regain: walking to the shop, staying alert for family, reducing pain, avoiding hospital, continuing work or living at home. Explore symptoms, mood, cognition, sleep, continence, nutrition, mobility, loneliness, housing and caring. A numerical disease target matters only through its likely effect on outcomes that the person understands and values.

Map the current work of being a patient. Count tablets and administrations, monitoring, equipment, dietary rules, appointments, travel, phone calls and forms. Ask which task is hardest and what the person has stopped doing. Non-adherence may be a rational response to competing demands, adverse effects, cost or unclear benefit. Use teach-back and medicines reconciliation before labelling a choice as non-compliance.

Construct an interaction map. Link each medicine and intervention to an indication, intended benefit, time horizon and monitoring need. Identify therapeutic competition, such as an intervention that helps one condition but worsens another; duplicate prescribing; renal or hepatic constraints; anticholinergic or sedative load; and prescriptions continued after a temporary indication ended. Include over-the-counter products and medicines supplied by hospitals or other services.

Estimate benefit in context. Relative effects from a guideline may conceal a small absolute benefit at low baseline risk or a long time to benefit. Consider prognosis, frailty and competing mortality without using age alone to deny treatment. Conversely, do not stop effective symptom relief or secondary prevention simply because the list is long. Discuss uncertainty and separate prevention, symptom control and life-prolonging treatment.

Prioritisation is shared reasoning. Agree which problems need urgent control, which treatments deliver present benefit, which future risks matter and which burdens are unacceptable. NICE advises considering stopping treatments of limited benefit and choosing alternatives that improve quality of life. One change at a time often makes cause and effect interpretable, unless immediate harm requires faster action.

Mental and physical health should be reviewed together. Depression can reduce self-management, pain can worsen sleep and mood, and cognitive impairment can make a complex regimen unsafe. Do not attribute new symptoms to anxiety without assessment. Check capacity for specific decisions when indicated, maximise supported decision making and involve carers with consent while retaining the patient’s voice.

Coordination prevents contradictory care. Create one plan that lists priorities, agreed targets, medicines changed, contingency advice and named ownership. Share it across primary, community, pharmacy, social care and specialist teams using lawful information routes. When recommendations conflict, contact the relevant specialist rather than asking the patient to arbitrate. Plan appointments together when possible.

Review is longitudinal. After a medicine reduction, monitor for withdrawal, rebound, recurrence and functional change. After relaxing a target, check that symptoms and avoidable acute risk remain controlled. Ask whether the new plan reduced effort and improved the chosen outcome. Revisit goals after admission, bereavement, functional decline or a new diagnosis because the balance of benefit and burden changes.

Inequality changes feasibility. Advice requiring transport, refrigeration, digital access, dexterity or stable housing may fail despite motivation. Ask practical questions and arrange support, reasonable adjustments or simplified supply. A blister pack is not a universal solution and can create errors after frequent medicine changes; involve the dispensing pharmacy and assess whether it solves the actual problem.

In assessment settings, the strongest answer usually integrates rather than adds another disease-specific task. Explain the trade-off, identify immediate safety concerns, clarify what matters, simplify with monitoring and coordinate. For WPBA, show that the patient’s goal altered the plan and that changes were followed through, not simply that a medication count was reduced.